In this episode of the Psychedelic Medicine Podcast, Nigel Denning, MA, MPsych, joins to discuss the reasons profound psychedelic experiences don’t always lead to lasting change. Nigel is a Counselling Psychologist and Director of Integrative Psychology & Medicine, with nearly 40 years of experience working with psychedelic and non-ordinary states. He has trained with MAPS, and served as co-lead therapist on three psychedelic clinical trials.
Read MoreIn this episode of the Psychedelic Medicine Podcast, Fernando Rivas, MD, joins to unpack the safety and screening considerations for ibogaine therapy. Dr. Rivas is an emergency physician with over 15 years of clinical experience. As Chief Medical Officer of Transcend Clinic, he has led the development of innovative treatment protocols in addiction medicine and the clinical application of ibogaine.
Read MoreIn this episode of the Psychedelic Medicine Podcast, Alexander Lebedev, MD, PhD joins to discuss psychedelic medicine and psychosis. Dr. Lebedev is a physician-scientist, medical AI engineer, and entrepreneur working at the frontier of health and technology. His work spans collective societal dynamics, psychedelics, and medical AI; he leads Lebedev Labs and is co-founder of Dreamseer and Once Wellbeing Center.
Read MoreIn this episode of the Psychedelic Medicine Podcast, Arsalan Azam, MD joins to unpack the intersection between psychedelics and GLP-1s. Dr. Azam, founder of Daydream MD, completed his residency in Emergency Medicine at the Metropolitan/Harlem Emergency Medicine Residency program in New York before practicing emergency medicine nationwide. Drawing on that experience, he developed a comprehensive ketamine-assisted therapy practice and now blends functional medicine with personalized GLP-1 services to help patients achieve sustainable, biologically tailored health outcomes.
Read MoreIn this episode of the Psychedelic Medicine Podcast, Dori Lewis, MA, MEd, LPC-S returns to discuss the differences between psilocybin and ketamine. Dori is the Clinical Director of Elemental Psychedelics and Owner/Operator of Reflective Healing in Fort Collins Colorado. As a clinician, she blends transpersonal psychology, depth work, and psychedelic-assisted therapy within a model that centers the therapeutic relationship. To date, she has stewarded over 100 ketamine therapy sessions, more than 200 mushroom sessions, and numerous group ceremonies.
Read MoreIn this episode of the Psychedelic Medicine Podcast, Katie Fassbinder, MD joins to explore how to choose the right ketamine clinic. Dr. Fassbinder is the Faculty Medical Lead for ketamine-assisted psychotherapy training at Elemental Psychedelics and a practicing psychiatrist based in Wisconsin with over 20 years of experience. She also directs mental health and KAP programming at Promega and has worked extensively in public-sector mental health systems.
Read MoreIn the 200th episode of the Psychedelic Medicine Podcast, Ismail Lourido Ali, JD joins to discuss the future of psychedelic medicine. Ismail serves as MAPS Co-Executive Director and has been actively participating in the drug policy reform movement for over a decade, informed by half a lifetime of diverse personal experience with psychedelics and other substances.
Read MoreIn this episode, Dr. WaiFung Tsang, DClinPsy joins to discuss the intersection of psychedelics and neurodiversity. Dr. Tsang is a clinical research psychologist from Hong Kong, musician, and student of Shipibo curanderismo. He is the co-founder of Onaya, an organisation dedicated to bridging Indigenous tradition and Western science, and research advisor for psychedelic veteran charity Heroic Hearts Project.
Read MoreIn this episode Amy Della Rocca, PMHNP joins to discuss Spravato, the FDA-approved prescription esketamine nasal spray, and its place in the field of psychedelic medicine. Amy is a psychiatric nurse practitioner and the Clinical Director of Marpa, a Spravato treatment center in New York.
Read MoreIn this episode, Michelle Weiner, DO, MPH returns to share her expertise on low-dose ketamine for chronic pain. Dr. Weiner is double board-certified in Interventional Pain Medicine, Physical Medicine, and Rehabilitation. She is founder of Neuropain Health delivering personalized integrative care treating the root cause of pain and suffering, both physical and emotional, using a multidisciplinary biopsychosocial approach with many years of clinical experience with ketamine-assisted therapy.
Read MoreIn this episode Dr. Simon Ruffell joins to discuss the research on ayahuasca for PTSD. Dr. Ruffell is a psychiatrist, researcher, and student of curanderismo (Amazonian shamanism) working at the intersection of Western psychiatry, traditional plant medicine, and Indigenous knowledge systems. He is Executive Director of Onaya, Lecturer in Psychology and Psychedelics at the University of Exeter, and Chief Medical Officer of MINDS, with a focus on integrative and relational approaches to healing and consciousness.
Read MoreIn this episode, Dr. Sean M. Viña joins to discuss the ways that social inequality can impact psychedelic healing. Dr. Viña is a sociologist with a PhD from Indiana University whose research focuses on psychedelics and mental health, and social inequality.
Read MoreIn this episode, Hunt Priest joins to discuss the intersection of psychedelic experiences and religion. Hunt is the founder of Ligare: A Christian Psychedelic Society and was a participant in the Johns Hopkins/NYU Psilocybin Study for Religious Leaders in 2016. The epiphanies he had at Hopkins forever changed the trajectory of his work and led him to start Ligare in 2021.
Read MoreIn this episode, Will Van Derveer, MD joins to unpack what we know about which psychedelic medicines are best suited to particular mental health conditions. Dr. Van Derveer has trained several thousand mental health professionals in psychedelic-assisted psychotherapy, provided ketamine assisted therapy to hundreds of people, and has staffed MDMA therapy trials with MAPS. His book, Psychedelic Therapy: A Revolutionary Approach to Restoring Your Mental Health and Reclaiming Your Life, will be published by Shambala in the spring of 2026.
Read MoreIn this episode, Alicia Bigelow, ND joins to discuss the potential of psychedelic medicine to support the menopause transition. Dr. Ali Bigelow is a naturopathic physician, ketamine provider and licensed psilocybin facilitator in Portland, OR. She leads individual and group retreats, enjoys incorporating live music into her sessions when desired, and is passionate about supporting those navigating life transitions, such as end of life and menopause, through her low dose group, Menomorphosis.
Read MoreIn this episode, Matthew W. Johnson, PhD returns to discuss how psychedelics can be leveraged to catalyze human agency. Dr. Johnson has been at the forefront of psychedelic research for 21 years, having conducted seminal research on the effects of psilocybin on mystical experience, personality, and treatment of cancer distress, major depressive disorder, and tobacco addiction. His work with tobacco addiction received the first federal funding for a classic psychedelic in the modern era of research.
Read MoreIn this episode, Dmitry Repin, PhD joins to discuss the intersection of bodily movement and psychedelics Dr. Repin is the co-founder of the Institute for Psychedelic Research at Tel Aviv University, holds a PhD in cognitive neuroscience, and is the producer and creative force behind the Everything Else Matters documentary.
Read MoreIn this episode, Psychedelic Medicine Podcast host, Dr. Lynn Marie Morski, provides the latest updates from the field of psychedelic medicine. Dr. Morski discusses the breakthrough therapy designation which a number of psychedelic compounds have received in the past few years, the most recent of which is BPL-003, a nasal spray formulation of 5-MeO-DMT. One of the exciting aspects of this new compound, Dr. Morski notes, is that it is shorter-acting than most serotonergic psychedelics—a feature which may make treatment with this substance less expensive and more accessible.
Read MoreIn this episode Matthew Hicks, ND, MS joins to dive into the topic of psilocybin-assisted group therapy for depression. Dr. Hicks is a research Investigator at the National University of Natural Medicine as well as a Naturopathic doctor and licensed psilocybin facilitator at Synaptic Institute.
Read MoreIn this episode Rotem Petranker, PhD joins to discuss the current state of research on microdosing psilocybin. Dr. Petranker is the co-founder of the Psychedelic Studies Research Program at the University of Toronto and the Canadian Centre for Psychedelic Science. He recently ran the world's largest randomized controlled trial on the effectiveness of microdosing psilocybin on Major Depressive Disorder.
Read More
